Assessing the safety and tolerability of low dose primaquine for transmission blocking in Cambodian patients with acute uncomplicated Plasmodium falciparum malaria

Assessing the safety and tolerability of low dose primaquine for transmission blocking in Cambodian patients with acute uncomplicated Plasmodium falciparum malaria

Objectives

The overall aim of this project is to assess the safety and tolerability of the WHO recommended addition of low dose (0.25mg/kg) primaquine, as a measure to help reduce the transmission of artemisinin resistant P. falciparum parasites, in Cambodian patients with uncomplicated P. falciparum who are glucose-6-phosphate dehydrogenase deficient (G6PDd). The objective is to measure and compare the Day 7 hemoglobin concentration between G6PDd and G6PD normal patients who are treated with dihydroartemisinin-piperaquine alone or combined with low dose primaquine.

PI Institution(s)

Principal Investigator (PI)

Funding source(s)

Partner(s)

Key facts

  • Dates
    Feb 2015 to Sep 2016
    Funding amount
    $150,000
    Country
    • Cambodia

MESA tags

  • Methodology
    Operational research, Product development & clinical research
    Theme(s)
    Drug-based strategies, Tools for elimination